GH 36
Alternative Names: GH-36Latest Information Update: 17 Feb 2023
At a glance
- Originator Suzhou Genhouse Bio
- Class Antineoplastics
- Mechanism of Action HDAC6 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Heart failure; Neuropathic pain
- Discontinued Cancer
Most Recent Events
- 16 Feb 2023 Discontinued for Cancer in China (unspecified route) before February 2023 (Suzhou Genhouse Bio pipeline, February 2023)
- 16 Feb 2023 Preclinical trials in Heart failure in China (unspecified route) before February 2023 (Suzhou Genhouse Bio, February 2023)
- 16 Feb 2023 Preclinical trials in Neuropathic pain in China (unspecified route) before February 2023 (Suzhou Genhouse Bio, February 2023)